{"id":"valsartan-fluvastatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Muscle pain (myalgia)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Hyperkalemia"}]},"_chembl":{"chemblId":"CHEMBL2220442","moleculeType":"Small molecule","molecularWeight":"411.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Valsartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from constricting blood vessels, thereby lowering blood pressure. Fluvastatin is a statin that inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, reducing LDL cholesterol and cardiovascular risk. Together, they address two major cardiovascular risk factors in a single formulation.","oneSentence":"This combination reduces blood pressure by blocking angiotensin II receptors (valsartan) and lowers cholesterol by inhibiting HMG-CoA reductase (fluvastatin).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:22.624Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension with hypercholesterolemia"},{"name":"Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy"}]},"trialDetails":[{"nctId":"NCT00309257","phase":"PHASE2","title":"Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2004-01","conditions":"Alport Syndrome","enrollment":9},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT03393377","phase":"NA","title":"Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2014-09","conditions":"Atherosclerosis","enrollment":20},{"nctId":"NCT03309618","phase":"NA","title":"Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2012-11","conditions":"Myocardial Infarction","enrollment":36},{"nctId":"NCT00821574","phase":"PHASE4","title":"Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-07","conditions":"Hypertension, Dyslypidaemia","enrollment":144},{"nctId":"NCT00171327","phase":"PHASE4","title":"Efficacy and Safety of Fluvastatin or Valsartan and Their Combination in Dyslipidemic Patients With Hypertension and Endothelial Dysfunction","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-07","conditions":"Hypertension, Dyslipidemia","enrollment":213},{"nctId":"NCT00407680","phase":"PHASE4","title":"Intensive Medical Treatment for Nephropathy Caused by Type 2 Diabetes With Hypertension","status":"UNKNOWN","sponsor":"Kitasato University","startDate":"2006-10","conditions":"Type 2 Diabetes Mellitus, Hypertension","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"valsartan, fluvastatin","genericName":"valsartan, fluvastatin","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces blood pressure by blocking angiotensin II receptors (valsartan) and lowers cholesterol by inhibiting HMG-CoA reductase (fluvastatin). Used for Hypertension with hypercholesterolemia, Cardiovascular risk reduction in patients requiring both antihypertensive and lipid-lowering therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}